Short Interest in Oculis Holding AG (NASDAQ:OCS) Increases By 105.6%
by Sarita Garza · The Markets DailyOculis Holding AG (NASDAQ:OCS – Get Free Report) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totaling 101,167 shares, a growth of 105.6% from the November 30th total of 49,197 shares. Approximately 0.2% of the company’s stock are short sold. Based on an average daily volume of 95,845 shares, the short-interest ratio is currently 1.1 days. Based on an average daily volume of 95,845 shares, the short-interest ratio is currently 1.1 days. Approximately 0.2% of the company’s stock are short sold.
Hedge Funds Weigh In On Oculis
Several large investors have recently made changes to their positions in the business. Bosun Asset Management LLC bought a new stake in Oculis during the 2nd quarter valued at approximately $378,000. Marshall Wace LLP acquired a new position in shares of Oculis during the second quarter worth approximately $393,000. Geode Capital Management LLC boosted its position in shares of Oculis by 27.7% in the second quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock valued at $571,000 after acquiring an additional 6,384 shares during the period. Bank of America Corp DE grew its stake in shares of Oculis by 2.2% in the second quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after acquiring an additional 878 shares during the last quarter. Finally, Woodline Partners LP increased its position in Oculis by 65.8% during the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock worth $1,474,000 after acquiring an additional 33,265 shares during the period. Institutional investors and hedge funds own 22.30% of the company’s stock.
Analyst Ratings Changes
A number of equities research analysts have issued reports on the stock. Stifel Nicolaus increased their target price on shares of Oculis from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Needham & Company LLC reissued a “buy” rating and set a $36.00 price objective on shares of Oculis in a research report on Tuesday, November 11th. JPMorgan Chase & Co. initiated coverage on Oculis in a research note on Friday, December 19th. They issued an “overweight” rating and a $38.00 target price on the stock. Bank of America cut their price target on Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a research note on Thursday, November 13th. Finally, HC Wainwright lifted their price target on Oculis from $36.00 to $42.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Eight research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $41.50.
Get Our Latest Stock Report on OCS
Oculis Stock Performance
Shares of OCS stock traded down $0.19 during trading on Friday, reaching $20.50. The company had a trading volume of 59,056 shares, compared to its average volume of 111,721. The company has a market capitalization of $1.07 billion, a PE ratio of -8.13 and a beta of 0.32. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.47. The firm’s 50 day simple moving average is $20.00 and its two-hundred day simple moving average is $18.90. Oculis has a one year low of $14.00 and a one year high of $23.08.
Oculis (NASDAQ:OCS – Get Free Report) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.10. Oculis had a negative net margin of 12,915.42% and a negative return on equity of 80.82%. The company had revenue of $0.31 million for the quarter, compared to analyst estimates of $0.23 million. Sell-side analysts forecast that Oculis will post -2.09 earnings per share for the current year.
About Oculis
Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.
Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.